Published in Vasc Health Risk Manag on January 01, 2006
Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2005) 9.58
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 5.59
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost (2004) 3.95
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA (2006) 3.41
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost (2004) 1.87
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med (2005) 1.82
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost (2003) 1.53
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res (1994) 1.33
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost (2006) 1.25
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther (1994) 1.23
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18
Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia (1999) 1.14
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost (1997) 1.12
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost (2001) 1.12
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest (1983) 1.12
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost (1998) 1.10
Thrombogenicity of prothrombin complex concentrates. Thromb Res (1999) 1.09
Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet (1988) 1.09
Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost (2002) 1.09
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia (2004) 1.08
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost (2006) 1.07
Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis (1998) 0.98
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia (1999) 0.97
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis (2000) 0.96
Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia (2004) 0.95
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med (1981) 0.94
Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia (2002) 0.94
Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion (1990) 0.92
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol (2003) 0.88
Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl (1998) 0.88
Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol (1999) 0.88
Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis (2000) 0.88
Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis (1990) 0.87
Mechanism of action of recombinant activated factor VII: an update. Semin Hematol (2006) 0.86
Dosing and monitoring NovoSeven treatment. Haemostasis (1996) 0.86
First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost (2002) 0.85
Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost (1996) 0.84
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia (2001) 0.84
NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds. Haemostasis (1996) 0.84
Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis (1996) 0.83
Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia (2005) 0.83
Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis (1996) 0.82
Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis (1999) 0.81
Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia (2002) 0.81
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis (2000) 0.80
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol (2002) 0.79
Thrombosis associated with the use of recombinant activated factor VII: profiling two events. Thromb Haemost (2004) 0.78
The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb (2002) 0.78
Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia (1998) 0.78
Therapeutic decision-making in inhibitor patients. Am J Hematol (2006) 0.77
Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis (1998) 0.77
Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis (1998) 0.76
Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Neth J Med (1998) 0.76
Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia (2002) 0.76
Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet (2010) 0.98
A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore. Ann Acad Med Singapore (2016) 0.81
VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metab Pharmacokinet (2009) 0.79
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther (2014) 0.79
Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. Ann Hematol (2008) 0.79
Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol (2003) 0.79
Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution. Thromb Haemost (2009) 0.79
Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. Int J Hematol (2011) 0.79
Patient-reported health preferences of anticoagulant-related outcomes. J Thromb Thrombolysis (2015) 0.78
Thrombosis associated with the use of recombinant activated factor VII: profiling two events. Thromb Haemost (2004) 0.78
Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in singapore. Ann Acad Med Singapore (2013) 0.76
A patient with extramedullary acute myeloid leukaemia involving the brachial plexus: Case report and review of the literature. Turk J Haematol (2008) 0.75
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. Am J Hematol (2006) 0.75
Thirty Years of Bone Marrow Transplantation in the Singapore General Hospital. Ann Acad Med Singapore (2016) 0.75
Haemophilia in 21st century Singapore. Ann Acad Med Singapore (2009) 0.75
Validity of current recommendation for peri-operative interruption of warfarin in Asians. J Thromb Thrombolysis (2010) 0.75